| Filed On | Filing |
|---|---|
| 15 Sep 2026 |
8-K: Regulation FD Disclosure
Parabilis Medicines, Inc. is updating its guidance to reflect its intention to present updated clinical data from the ongoing Phase 1/2 study of zolucatetide in desmoid tumor patients in an oral presentation at the European Society for M... |
| 02 Sep 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 25 Aug 2026 | 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure |
| 13 Aug 2026 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 11 Jun 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
Loading...
